[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 14, Number 2 (4-2016) ::
IJRR 2016, 14(2): 99-104 Back to browse issues page
Bone marrow radiation dosimetry of high dose 131I treatment in differentiated thyroid carcinoma patients
Y. Parlak, Dr. M. Demir , I. Cavdar, S. Ereees, G. Gumuser, B. Uysal, G. Capa Kaya, M. Koç, E. Sayit
Istanbul University , demirm@istanbul.edu.tr
Abstract:   (1480 Views)

Background: Radiation absorbed dose to the red bone marrow, a critical organ in the therapy of thyroid carcinoma, is generally kept below 2 Gy for non-myeloablative therapies. The aim of this study was to calculate bone marrow radiation dose by using MIRDOSE3 package program and to optimize the safe limit of activity to be administered to the thyroid cancer patients. Materials and Methods: In this study, 83 thyroid cancer patients were divided into 3 groups based on the amount of activity administered into the body. In the groups, 3700 MBq, 5550 MBq and 7400 MBq activities were used respectively. The curves of time-activity were drawn from blood samples counts and effective half-life and residence time were calculated. Correlations of bone marrow radiation dose and radioiodine effective half-life were determined as a function of administered activity via ANOVA test. Tg levels and tumour diameters were compared using Spearman’s correlation. Results: The effective half-lives of 131I for three groups of whole-body, receiving 3700 MBq, 5550 MBq and 7400 MBq were calculated as 20.57±5.4, 17.8±5.8 and 18.7±3.9 hours, respectively. The average bone marrow doses for 3 groups of patients were 0.32±0.08 Gy, 0.42±0.14 Gy and 0.60±0.24 Gy, respectively. Conclusion: It was concluded that, the bone marrow dose to the patients still remains within the recommended level even after administering an activity of 7400 MBq of 131I to the patients.

Keywords: Radioiodine treatment, bone marrow dosimetry, MIRDOSE3, thyroid cancer
Full-Text [PDF 523 kb]   (642 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Send email to the article author

Add your comments about this article
Your username or email:

Write the security code in the box >

DOI: 10.18869/acadpub.ijrr.14.2.99

XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Parlak Y, Demir M, Cavdar I, Ereees S, Gumuser G, Uysal B, et al . Bone marrow radiation dosimetry of high dose 131I treatment in differentiated thyroid carcinoma patients. IJRR. 2016; 14 (2) :99-104
URL: http://ijrr.com/article-1-1712-en.html
Volume 14, Number 2 (4-2016) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.051 seconds with 809 queries by yektaweb 3448